Novartis Finance Chief Rules Out Large M&A
Two Thirds Of Mega-Mergers ‘Fail’
While the correction of the biotech markets downwards increases the chances of bolt-on deals, even with the reduced prices, interesting assets are not so easy to come by, so says Novartis CFO Harry Kirsch.
You may also be interested in...
Cidara gets $30m up front for US rights to the weekly echinocandin candidate for candidemia and invasive candidiasis. Takeda walks away from oncolytic virus candidate licensed from Turnstone.
Among equity investors there is concern about the impact of macroeconomic headwinds on second-quarter earnings. The first two big life sciences companies’ reports did nothing to alleviate those concerns.
In this week's podcast version of Five Must-Know Things: Novo obesity drugs in US cost-effectiveness spotlight; Biogen’s growth challenges; Novartis’s view on large M&A; pharma’s Q2 outlook; and MSD on Lagevrio.